Multaq (dronedarone) is not a beta blocker. It is a Class III antiarrhythmic drug, a distinct category of heart medication that works through different mechanisms than beta blockers do. The confusion is understandable because both drugs are prescribed for atrial fibrillation, and Multaq does share some overlapping properties with beta blockers. But the two belong to separate drug classes and play different roles in treatment.
How Multaq Is Classified
Antiarrhythmic drugs are organized into four categories, known as the Vaughan-Williams classes. Beta blockers fall into Class II. Multaq is primarily classified as Class III, which means its main job is to stabilize the heart’s electrical rhythm rather than simply slow the heart rate. What makes Multaq unusual is that it has properties spanning all four Vaughan-Williams classes to some degree, including mild beta-blocking activity. That overlap is likely why some people wonder whether it’s a beta blocker. The FDA notes that the contribution of each of these activities to Multaq’s overall clinical effect is unknown.
How Multaq Works Differently
Beta blockers work by blocking adrenaline’s effects on the heart. This slows the heart rate and lowers blood pressure, making them useful for rate control in people who are living with atrial fibrillation rather than trying to eliminate it.
Multaq takes a broader approach. It blocks multiple types of ion channels in heart cells, including sodium, calcium, and potassium channels. It also inhibits a specific channel called HCN4 that helps set the heart’s natural pacemaker rhythm. By affecting several electrical pathways at once, Multaq aims to prevent abnormal heart rhythms from starting in the first place. Research shows its effects on sodium and calcium channels are “state-dependent,” meaning the drug preferentially targets heart tissue that is already behaving abnormally, which may give it a selective effect on the upper chambers of the heart where atrial fibrillation originates.
In practical terms, beta blockers are rate-control drugs: they keep a fast, irregular heartbeat from racing out of control. Multaq is a rhythm-control drug: it tries to keep the heart in its normal sinus rhythm so episodes of atrial fibrillation or flutter happen less often.
What Multaq Is Prescribed For
The FDA approved Multaq specifically to reduce the risk of hospitalization in people who are currently in normal sinus rhythm but have a history of paroxysmal or persistent atrial fibrillation. It was designed as an alternative to amiodarone, an older and more potent antiarrhythmic that carries significant long-term side effects involving the thyroid, lungs, and eyes. Multaq was developed to offer a similar rhythm-control benefit with a better safety profile, though it is generally considered less effective than amiodarone at maintaining sinus rhythm.
The 2023 ACC/AHA guidelines list dronedarone as an option for maintaining sinus rhythm in patients without recent decompensated heart failure or severe left ventricular dysfunction. Other rhythm-control alternatives include flecainide, propafenone, dofetilide, and sotalol, each with its own set of restrictions depending on the patient’s heart structure and function.
Taking Multaq With Beta Blockers
Because Multaq and beta blockers target different aspects of atrial fibrillation, they are sometimes prescribed together. However, this combination requires caution. In clinical trials, patients taking Multaq alongside a beta blocker experienced bradycardia (an abnormally slow heart rate) more frequently than those on either drug alone. If you’re taking both, your doctor will typically monitor your heart rate closely, especially early in treatment.
Important Safety Concerns
Multaq carries serious restrictions that set it apart from most beta blockers. It is contraindicated in people with permanent atrial fibrillation, meaning those whose doctors have decided not to attempt restoring normal rhythm. A large trial called PALLAS, which tested dronedarone in patients with permanent atrial fibrillation, was stopped early because patients on the drug had significantly higher rates of death (primarily from arrhythmia), stroke, and heart failure hospitalization compared to placebo.
A separate trial, ANDROMEDA, tested Multaq in patients with moderate to severe heart failure. That trial was also terminated early after the mortality rate in the dronedarone group reached 8.1%, compared to 3.8% in the placebo group. The excess deaths were primarily linked to worsening heart failure. Because of these findings, Multaq is not used in patients with severe heart failure or significantly reduced heart pumping function.
There have also been reports of serious liver injury. Two cases of acute liver failure were reported after the drug’s approval in 2009, prompting the FDA to recommend periodic liver function monitoring during treatment. Multaq also interacts with several other medications, particularly those processed through the same liver enzyme pathway (CYP 3A4), so your prescriber will review your full medication list before starting it.
Where Multaq Fits in AF Treatment
The choice between rate control and rhythm control is one of the central decisions in managing atrial fibrillation. For patients who tolerate their irregular rhythm reasonably well, rate-control drugs like beta blockers and calcium channel blockers are often the first step. For those who continue to have symptoms despite rate control, or whose doctors want to restore and maintain normal rhythm, antiarrhythmic drugs like Multaq enter the picture.
Among the rhythm-control options, Multaq occupies a middle ground. It is less effective than amiodarone at preventing atrial fibrillation recurrence, but it avoids many of amiodarone’s organ toxicities. It is an option for patients without significant structural heart disease or heart failure. For patients with reduced heart function, amiodarone and dofetilide are typically the only antiarrhythmic choices, since most other drugs in this category, including Multaq, are either unsafe or poorly tolerated in that population.